IMPROVING THE EFFICIENCY OF HAART WITH METHADONE AND BUPRENORPHINE TREATMENT IN HIV-INFECTED INJECTING DRUG USERS

Authors

  • D. H. Zhyvytsa
  • V. H. Kazeka

DOI:

https://doi.org/10.11603/1681-2727.2016.3.6885

Keywords:

HIV, HAART, CD4-lymphocyte, HIV viral load, buprenorphine, methadone, injecting drug users.

Abstract

The study evaluated the impact of methadone (buprenorphine) maintenance treatment (MMT) on immunological and virological efficiency of HAART in HIV-infected injecting drug users (IDUs). 65 HIV-infected patients, IDUs, were under the supervision and they were divided into two groups. The first group included 33 patients who were on MMT with methadone or buprenorphine. The second group included 32 patients who did not receive MMT. After the enrollment, all patients started receiving HAART. It was found that in patients with HIV infection the substitution maintenance therapy significantly increases the immunological and virological efficiency of HAART after the 12 months of treatment, increases the efficiency of clinical examination, and allows starting HAART in time at the absence of severe immunosuppression, which significantly improves the immunological effectiveness of HAART.

References

VIL-infektsiya v Ukrayini: Inform. byuletenʹ. – Kyyiv, 2012 – № 38. – 17 s.

Quinn T.C. HIV epidemiology and the effects of antiviral therapy on longterm consequences / T.C. Quinn // AIDS. – 2008. – Vol. 22, N 3. – Р. 7-12.

Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: A nationwide population–based cohort study / M.V. Larsen, L.H. Omland, J. Gerstoft [et al.] // Scand. J. Infect. Dis. – 2010. – Vol. 42, N 11-12. – P. 917-923.

The Antiretroviral Therapy Cohort Collaboration Study Group. Causes of Death in HIV-1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies / J. Gill, M. May, M. Saag [et al.] // Clin. Infect. Dis. – 2010. – Vol. 50, N 10. – Р. 1387-1396.

Global trends in antiretroviral resistance in treatment – naive individuals with HIV after rollout of antiretroviral treatment in resourcelimited settings: a global collaborative study and meta–regression analysis / R.K. Gupta, M.R. Jordan, B.J. Sultan [et al.] // Lancet. – 2012. – N 380. – P. 1250-1258.

Bulekov I.S. Narkopotrebleniye kak glavnyy element nepriverzhennosti VAART. Mozhno li sformirovat' priverzhennost' v aktivnogo narkopotrebitelya / I.S. Bulekov // VICH-infektsiya i immunosupressii. – 2011. – T. 3, № 4. – S. 20-24.

Vliyaniye narkopotrebleniya na obrashchayemost' za lecheniyem VICH infektsii v Sankt-Peterburge i Orenburge / O.S. Levina, A.A. Yakovleva, V.A. Odinokova [i dr.] // VICH-infektsiya i immunosupressii. – 2010. – T. 2, № 1.– S. 78-86.

Hill L. Drug interactions in the treatment of patients with HIV and psychiatric disorders. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics / L. Hill, K.C. Lee // Ann. Pharmacother. – 2013. – Vol. 47, N 1. – Р. 75-89.

Stigmatizatsiya u bol'nykh s VICH-infektsiyey i soputstvuyushchey opiynoy narkomaniyey / D.A. Lioznov, S.L. Nikolayenko, A.A. Zhigalov [i dr.] // VICH-infektsiya i immunosupressii. – 2012.– T. 4, № 3.– S. 52-56.

Sarankov YU.A. Priverzhennost' vysokoaktivnoy antiretrovirusnoy terapii (VAART) sredi potrebiteley in"yektsionnykh narkotikov: effektivnyye programmy vmeshatel'stv: obzor nauchnoy literatury / YU.A. Sarankov // «SPID Fond Vostok Zapad» (AIDS Foundation East West – AFEW). – 2005. – 47 s.

Klinichnyy protokol antyretrovirusnoyi terapiyi VIL–infektsiyi u doroslykh ta pidlitkiv / Zatv. nakazom MOZ Ukrayiny vid 12.07.2010 № 551. – K.: MOZ Ukrayiny, 2010. – 164 s.

Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods / P. Roux, C. Kouanfack, J. Cohen [et al.] // J. Acquir. Immune Defic. Syndr. – 2011. – Vol. 57, N 1. – P. 40-43.

Bartlett Dzh. Klinicheskiye aspekty VICH-infektsii / Dzh. Bartlett, Dzh. Galant. P. Fal. – M.: R. Valent, 2012. – 490 s.

Prichiny prekrashcheniya VAART. Rezul'taty dlitel'nogo nablyudeniya za bol'nymi s VICH-infektsiyey / S.A. Dvorak, Ye.V. Stepanova, N.V. Sizova [i dr.] // VICH-infektsiya i immunosupressii.– 2011. – T. 3, № 3.– S. 52-57.

A retrospective observational study of low-level viraemia and its immunological and virological significance: which outcome to expect / J. Silva, K. Pereira, J. Rijo [et al.] // J. Int. AIDS Soc. – 2014. – Vol. 17, N 3. – P. е19668.

Published

2016-11-14

How to Cite

Zhyvytsa, D. H., & Kazeka, V. H. (2016). IMPROVING THE EFFICIENCY OF HAART WITH METHADONE AND BUPRENORPHINE TREATMENT IN HIV-INFECTED INJECTING DRUG USERS. Infectious Diseases – Infektsiyni Khvoroby, 1(3), 28–32. https://doi.org/10.11603/1681-2727.2016.3.6885

Issue

Section

Original investigations